CA2868648A1 - Compounds for enhancing blood flow to the retina and optic nerve - Google Patents
Compounds for enhancing blood flow to the retina and optic nerve Download PDFInfo
- Publication number
- CA2868648A1 CA2868648A1 CA2868648A CA2868648A CA2868648A1 CA 2868648 A1 CA2868648 A1 CA 2868648A1 CA 2868648 A CA2868648 A CA 2868648A CA 2868648 A CA2868648 A CA 2868648A CA 2868648 A1 CA2868648 A1 CA 2868648A1
- Authority
- CA
- Canada
- Prior art keywords
- eye
- pressure
- muscle
- eyelid
- glaucoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 94
- 230000017531 blood circulation Effects 0.000 title claims description 35
- 210000001328 optic nerve Anatomy 0.000 title claims description 24
- 210000001525 retina Anatomy 0.000 title claims description 13
- 230000002708 enhancing effect Effects 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 75
- 230000000694 effects Effects 0.000 claims description 154
- 208000010412 Glaucoma Diseases 0.000 claims description 89
- 230000009467 reduction Effects 0.000 claims description 53
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 230000001965 increasing effect Effects 0.000 claims description 30
- 208000030533 eye disease Diseases 0.000 claims description 19
- 229960002870 gabapentin Drugs 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 12
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 10
- 206010030043 Ocular hypertension Diseases 0.000 claims description 7
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 208000001344 Macular Edema Diseases 0.000 claims description 5
- 206010025415 Macular oedema Diseases 0.000 claims description 5
- 201000010230 macular retinal edema Diseases 0.000 claims description 5
- 206010061323 Optic neuropathy Diseases 0.000 claims description 4
- 208000020911 optic nerve disease Diseases 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- 206010038903 Retinal vascular occlusion Diseases 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 208000038015 macular disease Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 208000021921 corneal disease Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 abstract description 183
- 230000009471 action Effects 0.000 abstract description 36
- 210000001508 eye Anatomy 0.000 description 373
- 210000000744 eyelid Anatomy 0.000 description 167
- 230000004397 blinking Effects 0.000 description 85
- 108030001720 Bontoxilysin Proteins 0.000 description 83
- 229940053031 botulinum toxin Drugs 0.000 description 83
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 76
- 238000002347 injection Methods 0.000 description 76
- 239000007924 injection Substances 0.000 description 76
- 239000000203 mixture Substances 0.000 description 71
- 239000003814 drug Substances 0.000 description 60
- 229940079593 drug Drugs 0.000 description 56
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 53
- 229960004194 lidocaine Drugs 0.000 description 52
- 239000003889 eye drop Substances 0.000 description 51
- 239000003053 toxin Substances 0.000 description 49
- 231100000765 toxin Toxicity 0.000 description 49
- 108700012359 toxins Proteins 0.000 description 49
- 229940012356 eye drops Drugs 0.000 description 41
- 238000002560 therapeutic procedure Methods 0.000 description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 230000007423 decrease Effects 0.000 description 38
- 210000004087 cornea Anatomy 0.000 description 37
- 230000006378 damage Effects 0.000 description 33
- 238000001356 surgical procedure Methods 0.000 description 32
- 230000001225 therapeutic effect Effects 0.000 description 32
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 30
- 239000003795 chemical substances by application Substances 0.000 description 30
- 230000001603 reducing effect Effects 0.000 description 26
- 230000008901 benefit Effects 0.000 description 24
- 238000011282 treatment Methods 0.000 description 23
- 206010049816 Muscle tightness Diseases 0.000 description 20
- 230000003247 decreasing effect Effects 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 230000008859 change Effects 0.000 description 17
- 201000004569 Blindness Diseases 0.000 description 15
- 230000033001 locomotion Effects 0.000 description 14
- 239000002581 neurotoxin Substances 0.000 description 14
- 231100000618 neurotoxin Toxicity 0.000 description 14
- 229960004679 doxorubicin Drugs 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- 206010040954 Skin wrinkling Diseases 0.000 description 12
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 12
- 230000001815 facial effect Effects 0.000 description 12
- 230000004118 muscle contraction Effects 0.000 description 12
- 101710138657 Neurotoxin Proteins 0.000 description 11
- 239000002876 beta blocker Substances 0.000 description 11
- 229940097320 beta blocking agent Drugs 0.000 description 11
- 230000010412 perfusion Effects 0.000 description 11
- 230000004393 visual impairment Effects 0.000 description 11
- 230000037303 wrinkles Effects 0.000 description 11
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 10
- 229930195712 glutamate Natural products 0.000 description 10
- 230000001537 neural effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 9
- 230000003444 anaesthetic effect Effects 0.000 description 9
- 239000003158 myorelaxant agent Substances 0.000 description 9
- 229960001722 verapamil Drugs 0.000 description 9
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 8
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 8
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 8
- 230000007547 defect Effects 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 210000001097 facial muscle Anatomy 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000004410 intraocular pressure Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000004321 preservation Methods 0.000 description 8
- 230000002459 sustained effect Effects 0.000 description 8
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 229960003299 ketamine Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000004220 muscle function Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000003313 weakening effect Effects 0.000 description 7
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 210000004699 muscle spindle Anatomy 0.000 description 6
- 108091008709 muscle spindles Proteins 0.000 description 6
- 239000004090 neuroprotective agent Substances 0.000 description 6
- 238000012876 topography Methods 0.000 description 6
- 208000003435 Optic Neuritis Diseases 0.000 description 5
- 108010055044 Tetanus Toxin Proteins 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 206010005159 blepharospasm Diseases 0.000 description 5
- 230000000744 blepharospasm Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 229940094657 botulinum toxin type a Drugs 0.000 description 5
- 229960003150 bupivacaine Drugs 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 210000000715 neuromuscular junction Anatomy 0.000 description 5
- 230000003518 presynaptic effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 208000004644 retinal vein occlusion Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 4
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229960000794 baclofen Drugs 0.000 description 4
- 229940089093 botox Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- -1 gabatoentin Chemical compound 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000003589 local anesthetic agent Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229960003404 mexiletine Drugs 0.000 description 4
- 229940035363 muscle relaxants Drugs 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 4
- 229960003946 selegiline Drugs 0.000 description 4
- 229940118376 tetanus toxin Drugs 0.000 description 4
- 229960001032 trihexyphenidyl Drugs 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 3
- 206010013486 Distractibility Diseases 0.000 description 3
- 206010063006 Facial spasm Diseases 0.000 description 3
- 208000004095 Hemifacial Spasm Diseases 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 208000029578 Muscle disease Diseases 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 201000007527 Retinal artery occlusion Diseases 0.000 description 3
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 3
- 229940035674 anesthetics Drugs 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229940098753 dysport Drugs 0.000 description 3
- 210000003560 epithelium corneal Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 229960004716 idoxuridine Drugs 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 229960003587 lisuride Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036640 muscle relaxation Effects 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000003733 optic disk Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000009258 post-therapy Methods 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000003994 retinal ganglion cell Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229960005333 tetrabenazine Drugs 0.000 description 3
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010010996 Corneal degeneration Diseases 0.000 description 2
- 239000008709 Curare Substances 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020852 Hypertonia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
- 206010035015 Pigmentary glaucoma Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 230000001090 anti-dopaminergic effect Effects 0.000 description 2
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001042 autoregulative effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 229940024774 benztropine mesylate Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008081 blood perfusion Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 2
- 229950011318 cannabidiol Drugs 0.000 description 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 2
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 2
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 2
- 229940115080 doxil Drugs 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000040 eye damage Toxicity 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000118 neural pathway Anatomy 0.000 description 2
- 230000010004 neural pathway Effects 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000004386 ocular blood flow Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 229960001549 ropivacaine Drugs 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 239000002708 spider venom Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
- 229950010357 tetrodotoxin Drugs 0.000 description 2
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
- 229960005344 tiapride Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000006496 vascular abnormality Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- CCXGETLCANRFGD-UHFFFAOYSA-N 1,3-dinitrooxypropan-2-yl nitrate;nitric acid Chemical class O[N+]([O-])=O.[O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O CCXGETLCANRFGD-UHFFFAOYSA-N 0.000 description 1
- CPFJLLXFNPCTDW-UHFFFAOYSA-N 3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane;methanesulfonic acid Chemical compound CS(O)(=O)=O.CN1C(C2)CCC1CC2OC(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011033 Corneal oedema Diseases 0.000 description 1
- 241000017055 Dipluridae Species 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000017934 GABA-B receptor Human genes 0.000 description 1
- 108060003377 GABA-B receptor Proteins 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 101710086426 Myotoxin Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical class [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030136 Oesophageal achalasia Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 230000004321 blink reflex Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000004781 bullous keratopathy Diseases 0.000 description 1
- 229960001290 butanilicaine Drugs 0.000 description 1
- VWYQKFLLGRBICZ-UHFFFAOYSA-N butanilicaine Chemical compound CCCCNCC(=O)NC1=C(C)C=CC=C1Cl VWYQKFLLGRBICZ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 201000004778 corneal edema Diseases 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- XXWFDPVOXNJASB-UHFFFAOYSA-N ethanol;phenol Chemical compound CCO.OC1=CC=CC=C1 XXWFDPVOXNJASB-UHFFFAOYSA-N 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000004399 eye closure Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 201000001948 hypertensive retinopathy Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000001232 limbus corneae Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229940112534 lumigan Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 201000000041 pigment dispersion syndrome Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000004461 rapid eye movement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 1
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 1
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940063629 sensorcaine Drugs 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 229940113006 travatan Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 229950002569 trimecaine Drugs 0.000 description 1
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/421,956 | 2003-04-24 | ||
| US10/421,956 US20040058313A1 (en) | 2002-04-24 | 2003-04-24 | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| CA2523363A CA2523363C (en) | 2003-04-24 | 2003-12-08 | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2523363A Division CA2523363C (en) | 2003-04-24 | 2003-12-08 | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2868648A1 true CA2868648A1 (en) | 2004-11-11 |
Family
ID=33415845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2868648A Abandoned CA2868648A1 (en) | 2003-04-24 | 2003-12-08 | Compounds for enhancing blood flow to the retina and optic nerve |
| CA2523363A Expired - Fee Related CA2523363C (en) | 2003-04-24 | 2003-12-08 | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2523363A Expired - Fee Related CA2523363C (en) | 2003-04-24 | 2003-12-08 | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040058313A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1622589B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006524185A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003297684A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0318269A (cg-RX-API-DMAC7.html) |
| CA (2) | CA2868648A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004096183A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
| PL206379B1 (pl) * | 2002-07-15 | 2010-08-31 | Alcon | Ulegająca bioerozji kompozycja do wytwarzania błony do dostarczania leków oftalmicznych i zastosowanie |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US20060073208A1 (en) | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
| EP2186518A1 (en) * | 2004-11-17 | 2010-05-19 | McLaurin, Joanne | Composition and methods for treatment of disorders of protein aggregation |
| JP2007051090A (ja) * | 2005-08-18 | 2007-03-01 | Pharma Foods International Co Ltd | 卵白ペプチドを有効成分として含有する血流改善剤 |
| WO2007041855A1 (en) * | 2005-10-13 | 2007-04-19 | Waratah Pharmaceuticals, Inc. | Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence |
| US20070197453A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Compositions and methods for treatment of disorders of protein aggregation |
| US20070197452A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Treatment of amyloid-related diseases |
| WO2007101353A1 (en) * | 2006-03-09 | 2007-09-13 | Waratah Pharmaceuticals Inc. | A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation |
| US20110028719A1 (en) * | 2006-05-19 | 2011-02-03 | Jacek Slon-Usakiewicz | Screening methods for amyloid beta modulators |
| JP5250548B2 (ja) | 2006-06-21 | 2013-07-31 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 疾患の治療のための補体h因子の標的化 |
| US20100173960A1 (en) * | 2006-09-21 | 2010-07-08 | Antonio Cruz | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases |
| US20100292157A1 (en) * | 2006-11-24 | 2010-11-18 | Antonio Cruz | Combination Treatments for Alzheimer's Disease and Similar Diseases |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| WO2008124931A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis |
| US20110105626A1 (en) * | 2007-04-12 | 2011-05-05 | Mclaurin Joanne | Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases |
| EP2148667B1 (en) | 2007-04-12 | 2013-05-22 | Waratah Pharmaceuticals, Inc. | Use of cyclohexanehexol derivatives in the treatment of ocular diseases |
| CA2683546A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies |
| US7632848B1 (en) * | 2007-10-04 | 2009-12-15 | Alan Brown Scott | Medical treatment of muscles by exposure to anesthetic drugs |
| US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
| AU2009296457A1 (en) * | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| EP2349233A4 (en) * | 2008-10-09 | 2012-04-18 | Waratah Pharmaceuticals Inc | USE OF SCYLLO-INOSITOLS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH MACULAR DEGENERATION |
| BR112012033119A2 (pt) | 2010-06-22 | 2016-10-25 | Univ Colorado Regents | anticorpos para o fragamento c3d do componente do complemento 3. |
| CN103068382A (zh) * | 2010-07-30 | 2013-04-24 | 阿勒根公司 | 用于皮肤修复的化合物和方法 |
| US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
| CA2830949A1 (en) * | 2011-04-07 | 2012-10-11 | Sensimed Sa | Device and method for detecting ophtalmic and/or brain diseases |
| SI2968461T1 (sl) | 2013-03-13 | 2023-01-31 | Genzyme Corporation | Fuzijski proteini, ki vsebujejo vezavna dela PDGF in VEGF in postopek njihove uporabe |
| RU2535115C1 (ru) | 2013-05-15 | 2014-12-10 | Бости Трейдинг Лтд | Фармацевтический состав, содержащий нейротоксин ботулина |
| CN106573961B (zh) | 2014-06-20 | 2022-01-04 | 豪夫迈·罗氏有限公司 | 基于chagasin的支架组合物、方法和应用 |
| CA2999279A1 (en) * | 2015-10-01 | 2017-04-06 | Goleini Inc. | Targeted expression of chloride channels and methods of use thereof |
| EP4538365A3 (en) | 2016-03-04 | 2025-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin e2 |
| US11096993B2 (en) | 2016-12-08 | 2021-08-24 | Gary E. Borodic | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals |
| US11123411B2 (en) | 2016-12-08 | 2021-09-21 | Gary E. Borodic | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals |
| CN110662549A (zh) * | 2017-05-01 | 2020-01-07 | 路易斯安娜州立大学监测委员会,农业和机械学院 | 用于治疗眼病的组合物和方法 |
| GB2578539B (en) | 2017-06-09 | 2022-08-10 | Univ Leland Stanford Junior | Compositions and methods for preventing or treating muscle conditions |
| CN112972444B (zh) * | 2021-02-19 | 2022-07-26 | 中国医学科学院整形外科医院 | 美西律在制备治疗和/或预防面颈部皮肤皱纹的产品中的应用 |
| CN113288784B (zh) * | 2021-06-11 | 2023-03-31 | 中国人民解放军陆军军医大学第一附属医院 | 泪道冲洗收水装置 |
| KR20260039752A (ko) | 2023-07-13 | 2026-03-20 | 크리야 테라퓨틱스, 인크. | 보체 경로 억제제 융합체 및 그의 사용 방법 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3545260A (en) * | 1967-10-31 | 1970-12-08 | Technicon Corp | Means and method for detection of glaucoma |
| US3585849A (en) * | 1968-10-09 | 1971-06-22 | American Optical Corp | Method and apparatus for measuring intraocular pressure |
| US3724263A (en) * | 1970-09-29 | 1973-04-03 | Bio Optronics Inc | Electrical digital display tonometer |
| US3963019A (en) * | 1974-11-25 | 1976-06-15 | Quandt Robert S | Ocular testing method and apparatus |
| US4186184A (en) * | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
| US4305399A (en) * | 1978-10-31 | 1981-12-15 | The University Of Western Australia | Miniature transducer |
| CH633952A5 (fr) * | 1980-03-14 | 1983-01-14 | Grounauer Pierre Alain | Dispositif de mesure des potentiels electriques de l'oeil. |
| US4485820A (en) * | 1982-05-10 | 1984-12-04 | The Johns Hopkins University | Method and apparatus for the continuous monitoring of hemoglobin saturation in the blood of premature infants |
| US4734275A (en) * | 1983-08-19 | 1988-03-29 | Research Corporation | Anti-curare agents |
| JPS61321A (ja) * | 1984-06-12 | 1986-01-06 | 株式会社トプコン | 非接触式眼圧計 |
| US4629424A (en) * | 1984-08-30 | 1986-12-16 | Integrated Ionics, Inc. | Intraoral ambient sensing device |
| US4771792A (en) * | 1985-02-19 | 1988-09-20 | Seale Joseph B | Non-invasive determination of mechanical characteristics in the body |
| US4628938A (en) * | 1985-12-09 | 1986-12-16 | Lee David A | Continuous applanation tonometer |
| EP0242580B1 (en) * | 1986-03-13 | 1993-04-28 | The Trustees Of Columbia University In The City Of New York | Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma |
| JPS63267331A (ja) * | 1986-12-27 | 1988-11-04 | Tokyo Optical Co Ltd | 非接触式眼圧計 |
| US5076274A (en) * | 1987-02-18 | 1991-12-31 | Canon Kabushiki Kaisha | Non-contact tonometer |
| US5183044A (en) * | 1987-06-30 | 1993-02-02 | Kabushiki Kaisha Topcon | Noncontact type tonometer |
| US4922913A (en) * | 1987-11-12 | 1990-05-08 | Waters Jr George E | Intraocular pressure sensor |
| US4860755A (en) * | 1988-02-08 | 1989-08-29 | Erath-Young Instrument Company, Inc. | Differential pressure applanation tonometer |
| US5165409A (en) * | 1988-08-23 | 1992-11-24 | Coan William M | Tonometry apparatus |
| US4951671A (en) * | 1988-08-23 | 1990-08-28 | Coan William M | Tonometry apparatus |
| US5005577A (en) * | 1988-08-23 | 1991-04-09 | Frenkel Ronald E P | Intraocular lens pressure monitoring device |
| US5109852A (en) * | 1990-06-08 | 1992-05-05 | Kaye David B | Method for sensing pressure in an object |
| US5217015A (en) * | 1990-06-08 | 1993-06-08 | Kaye David B | Pressure sensing device having transducer overlying and deforming eye |
| US5342283A (en) * | 1990-08-13 | 1994-08-30 | Good Roger R | Endocurietherapy |
| US5148807A (en) * | 1990-08-28 | 1992-09-22 | Ohio State University | Non-contact tonometer |
| US5209231A (en) * | 1990-11-02 | 1993-05-11 | University Of Connecticut | Optical glucose sensor apparatus and method |
| US5295495A (en) * | 1991-05-13 | 1994-03-22 | The Australian National University | Glaucoma testing from observations of optokinetic nystagmus |
| US5251627A (en) * | 1991-06-27 | 1993-10-12 | Morris Donald E | Non-invasive measurement of eyeball pressure using vibration |
| US5179953A (en) * | 1991-08-27 | 1993-01-19 | Jermik Systems, Ltd. | Portable diurnal intraocular pressure recording system |
| US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5375595A (en) * | 1993-03-17 | 1994-12-27 | The Regents Of The University Of Calif. | Apparatus and method for non-contact, acoustic resonance determination of intraocular pressure |
| US6350781B1 (en) * | 1994-01-14 | 2002-02-26 | Lee Shahinia, Jr. | Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine |
| CA2236368C (en) * | 1995-11-06 | 2001-10-23 | Somerset Pharmaceuticals, Inc. | Sublingual and buccal administration of selegiline |
| US6544193B2 (en) * | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
| US5830139A (en) * | 1996-09-04 | 1998-11-03 | Abreu; Marcio M. | Tonometer system for measuring intraocular pressure by applanation and/or indentation |
| US6120460A (en) * | 1996-09-04 | 2000-09-19 | Abreu; Marcio Marc | Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions |
| US5922746A (en) * | 1997-03-27 | 1999-07-13 | Allergan | Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| US6090847A (en) * | 1997-11-21 | 2000-07-18 | Allergan Sales, Inc. | EP2 -receptor agonists as neuroprotective agents for the eye |
| US6294583B1 (en) * | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| WO2000004898A1 (en) * | 1998-07-21 | 2000-02-03 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| US6545045B1 (en) * | 1998-12-24 | 2003-04-08 | Alcon Manufacturing, Ltd. | Prostaglandin E agonists for treatment of glaucoma |
| HRP20010581A2 (en) * | 1999-12-08 | 2002-08-31 | Warner Lambert Co | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy |
| US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
-
2003
- 2003-04-24 US US10/421,956 patent/US20040058313A1/en not_active Abandoned
- 2003-12-08 BR BRPI0318269-0A patent/BR0318269A/pt not_active Application Discontinuation
- 2003-12-08 EP EP03816832.4A patent/EP1622589B1/en not_active Expired - Lifetime
- 2003-12-08 JP JP2004571477A patent/JP2006524185A/ja active Pending
- 2003-12-08 CA CA2868648A patent/CA2868648A1/en not_active Abandoned
- 2003-12-08 CA CA2523363A patent/CA2523363C/en not_active Expired - Fee Related
- 2003-12-08 AU AU2003297684A patent/AU2003297684A1/en not_active Abandoned
- 2003-12-08 WO PCT/US2003/038740 patent/WO2004096183A1/en not_active Ceased
-
2012
- 2012-07-20 US US13/554,349 patent/US20120282242A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040058313A1 (en) | 2004-03-25 |
| WO2004096183A1 (en) | 2004-11-11 |
| BR0318269A (pt) | 2006-05-23 |
| US20120282242A1 (en) | 2012-11-08 |
| CA2523363A1 (en) | 2004-11-11 |
| EP1622589A1 (en) | 2006-02-08 |
| EP1622589B1 (en) | 2017-03-15 |
| CA2523363C (en) | 2015-02-10 |
| JP2006524185A (ja) | 2006-10-26 |
| EP1622589A4 (en) | 2009-07-15 |
| AU2003297684A1 (en) | 2004-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2523363C (en) | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders | |
| TWI323663B (en) | Use of botulinum toxin for the manufacture of medicament for treating sinus headache | |
| Tseng et al. | A randomized clinical trial of combined topical-intracameral anesthesia in cataract surgery | |
| US20020192239A1 (en) | Use of botulinum toxin for the treatment of chronic facial pain | |
| Anderson et al. | Comparison of preservative-free bupivacaine vs lidocaine for intracameral anesthesia: a randomized clinical trial and in vitro analysis | |
| Reis et al. | A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension | |
| US20080199452A1 (en) | Botulinum toxin compositions and methods | |
| Jaichandran et al. | Local anesthetic agents for vitreoretinal surgery: no advantage to mixing solutions | |
| Moss et al. | A comparison of the effects of timolol and epinephrine on intraocular pressure | |
| Di Donato et al. | Efficacy and comparison of 0.5% levobupivacaine with 0.75% ropivacaine for peribulbar anaesthesia in cataract surgery | |
| US20060067950A1 (en) | Clostridial neurotoxins for use in wound healing | |
| Pacella et al. | Levobupivacaine vs. racemic bupivacaine in peribulbar anaesthesia: a randomized double blind study in ophthalmic surgery. | |
| Barr et al. | Effects of adrenaline and hyaluronidase on plasma concentrations of lignocaine and bupivacaine after peribulbar anaesthesia. | |
| Orgül et al. | Therapeutic strategies for normal-tension glaucoma | |
| Irfan | Minimal orbicularis myectomy: does it relieve spasms in benign essential blepharospasm? | |
| Davidorf et al. | Treatment of the fellow eye in acute angle-closure glaucoma: a case report and survey of members of the American Glaucoma Society | |
| Ikeda et al. | Clinical significance of topical instillation technique in Japanese glaucoma patients | |
| Mohamad et al. | Neostigmine and ketorolac as adjuvants to local anesthetic through peribulbar block in patients undergoing vitrectomy surgeries: A randomized controlled trial | |
| Rana et al. | Comparative study between 0.5% bupivacaine versus 0.5% ropivacaine in peribulbar anesthesia for cataract surgery | |
| Abbas et al. | Efficacy of topical anaesthesia in reduction of oculocardiac reflex during squint surgery | |
| Schaefer et al. | 28 Chapter Neurotoxins for Therapeutic Chemodenervation | |
| Mansour et al. | Atracurium as an Adjunct to Local Anesthetic for Peribulbar Anesthesia in Cataract Surgery: A Controlled Randomized Clinical Study. | |
| Lu et al. | Subconjunctival trypsin injection for anterior chamber fibrin exudates in eyes with globe rupture following vitrectomy | |
| Smith et al. | Other dermatologic uses of botulinum toxin | |
| Stevens et al. | Injectable Fillers for Lower Eyelid Rejuvenation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141024 |
|
| FZDE | Dead |
Effective date: 20181106 |